UroGen Pharma Income Statement (2016-2026) | URGN

Income Statement Dec2016 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
13.03M11.35M16.17M13.56M16.60M16.10M18.09M17.19M21.14M20.85M23.53M18.78M21.85M25.20M24.57M20.25M24.21M27.48M37.84M50.96M
Cost of Revenue (Quarter)
1.43M1.24M1.59M1.52M1.85M2.02M2.26M2.27M2.44M2.37M2.29M1.73M2.23M2.45M2.47M2.33M3.55M3.28M3.29M4.14M
Gross Profit (Quarter)
11.61M10.11M14.59M12.04M14.76M14.08M15.83M14.93M18.70M18.48M21.24M17.05M19.62M22.75M22.09M17.92M20.66M24.20M34.55M46.82M
Operating items
Research & Development (Quarter)
12.12M11.92M13.08M12.70M12.64M13.09M14.48M12.50M11.58M10.23M11.30M15.49M15.40M11.36M14.89M11.39M18.91M14.01M14.31M0.21M
Selling, General & Administrative (Quarter)
22.30M21.62M21.42M21.30M20.83M19.07M21.63M24.47M22.49M21.75M24.55M27.30M30.06M28.94M34.86M34.97M43.20M37.58M39.35M51.49M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
34.43M33.55M34.50M34.00M33.47M32.16M36.11M36.97M34.08M31.98M35.85M42.79M45.46M40.30M49.75M46.36M62.11M51.59M53.66M51.70M
Operating Income (Quarter)
-22.82M-23.44M-19.91M-21.96M-18.71M-18.09M-20.28M-22.05M-15.38M-13.50M-14.61M-25.74M-25.84M-17.55M-27.66M-36.91M-41.45M-27.39M-19.11M-20.26M
EBIT (Quarter)
-22.82M-23.44M-19.91M-21.96M-18.71M-18.09M-20.28M-22.05M-15.38M-13.50M-14.61M-25.74M-25.84M-17.55M-27.66M-36.91M-41.45M-27.39M-19.11M-20.26M
Non-operating items
Interest & Investment Income (Quarter)
-0.10M-0.04M0.10M-0.00M0.13M0.48M0.05M0.06M-0.11M0.02M-1.82M1.61M1.71M0.27M2.75M2.11M-0.01M0.02M5.33M0.61M
Non Operating Income (Quarter)
-0.24M-0.02M-0.08M-0.00M0.10M0.04M-0.06M-0.01M-0.03M0.07M
Net income details
EBT (Quarter)
-25.91M-30.21M-27.32M-28.07M-26.66M-25.12M-28.18M-30.19M-24.08M-21.89M-22.16M-32.23M-33.37M-23.58M-34.86M-43.45M-48.92M-34.40M-26.64M-28.35M
Tax Provisions (Quarter)
0.31M-25.47M0.33M0.03M0.71M0.69M0.02M0.05M-0.01M5.64M0.05M0.04M0.09M-28.71M0.39M1.01M-1.05M-0.18M-4.77M
Profit After Tax (Quarter)
-26.32M-30.25M-110.55M-28.39M-26.69M-25.93M0.05M-30.21M-24.14M-21.88M-26.02M-32.34M0.01M0.27M-37.51M-0.04M-49.95M-33.33M-26.40M-23.57M
Income from Continuing Operations (Quarter)
-26.22M-30.21M-1.85M-28.39M-26.69M-25.83M-28.87M-30.21M-24.14M-21.88M-27.80M-32.29M-33.40M-23.67M-6.15M-43.84M-49.94M-33.35M-26.46M-23.57M
Consolidated Net Income (Quarter)
-26.22M-30.21M-1.85M-28.39M-26.69M-25.83M-28.87M-30.21M-24.14M-21.88M-27.80M-32.29M-33.40M-23.67M-6.15M-43.84M-49.94M-33.35M-26.46M-23.57M
Income towards Parent Company (Quarter)
-26.22M-30.21M-1.85M-28.39M-26.69M-25.83M-28.87M-30.21M-24.14M-21.88M-27.80M-32.29M-33.40M-23.67M-6.15M-43.84M-49.94M-33.35M-26.46M-23.57M
Net Income towards Common Stockholders (Quarter)
-26.22M-30.21M-1.85M-28.39M-26.69M-25.83M-28.87M-30.21M-24.14M-21.88M-27.80M-32.29M-33.40M-23.67M-6.15M-43.84M-49.94M-33.35M-26.46M-23.57M
Additional items
EPS (Basic) (Quarter)
-1.17-1.35-0.08-1.25-1.18-1.13-1.27-1.30-1.03-0.68-0.96-0.97-0.91-0.55-0.14-0.92-1.05-0.69-0.55-0.47
Shares Outstanding (Quarter)
22.33M22.38M22.35M22.63M22.70M22.80M22.81M23.28M23.46M32.30M28.83M33.38M36.82M43.10M42.88M47.42M47.74M48.06M48.12M50.18M
EBITDA (Quarter)
-22.82M-23.44M-19.91M-21.96M-18.71M-18.09M-20.28M-22.05M-15.38M-13.50M-14.61M-25.74M-25.84M-17.55M-27.66M-36.91M-41.45M-27.39M-19.11M-20.26M
Interest Expenses (Quarter)
0.00M-1.43M0.30M0.29M3.23M0.29M2.68M0.05M2.08M0.29M0.28M1.31M1.10M0.22M0.22M4.76M5.97M0.24M5.50M
Tax Rate (Quarter)
-1.20%93.23%-1.16%-0.12%-2.82%-2.44%-0.07%-0.22%0.04%-25.44%-0.17%-0.11%-0.39%82.36%-0.90%-2.07%3.06%0.67%16.83%